LENSAR Q2 Revenue Up 18%, Swings to Profit on Strong ALLY Adoption
LNSR sits 45% above its 52-week low of $4.95.
Summary
LENSAR reported Q2 2026 revenue of $16.5 million, up 18% year-over-year, and swung to a net profit of $3.5 million. Strong ALLY system placements and recurring revenue growth drove the beat, though cash reserves declined to $13.6 million.
Key Events · Earnings and Guidance · LNSR
-
Q2 Revenue Up 18%
Total revenue reached $16.5 million, up from $13.9 million in Q2 2025, driven by 20% growth in recurring revenue to $13.7 million.
-
Swings to Profitability
Net income was $3.5 million compared to a net loss of $1.8 million a year ago. Adjusted EBITDA was $3.6 million, the strongest quarterly performance to date.
-
ALLY Adoption Accelerates
10 ALLY systems were placed in Q2, bringing the total ALLY installed base to 215, up 30% year-over-year. Backlog stood at 13 systems as of June 30, 2026.
-
Procedure Volume Grows 13%
Procedure volume reached 58,682 in Q2 2026, up from 52,100 in Q2 2025, reflecting increased utilization of the installed base.
Analysis · LNSR · Industrial Applications And Services
A strong second quarter for LENSAR featured 18% revenue growth and a swing to profitability, driven by accelerating adoption of its ALLY robotic cataract laser system. The company placed 10 ALLY systems in the quarter, grew its installed base 30% year-over-year, and built a backlog of 13 systems pending installation. Recurring revenue, which makes up 83% of total revenue, grew 20%, and procedure volume rose 13%. The company also reported positive Adjusted EBITDA of $3.6 million, its strongest to date. However, cash and investments declined to $13.6 million from $18.0 million at year-end, reflecting continued investment in growth. The results validate the company's recurring revenue model and commercial strategy, but the shrinking cash position remains a key watch item.
At the time of this filing, LNSR was trading at $7.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $76.1M. The 52-week trading range was $4.95 to $13.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.